Pedro J. Beltran

6.5k total citations
52 papers, 2.2k citations indexed

About

Pedro J. Beltran is a scholar working on Molecular Biology, Endocrinology, Diabetes and Metabolism and Cancer Research. According to data from OpenAlex, Pedro J. Beltran has authored 52 papers receiving a total of 2.2k indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Molecular Biology, 15 papers in Endocrinology, Diabetes and Metabolism and 15 papers in Cancer Research. Recurrent topics in Pedro J. Beltran's work include Growth Hormone and Insulin-like Growth Factors (15 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Salmonella and Campylobacter epidemiology (7 papers). Pedro J. Beltran is often cited by papers focused on Growth Hormone and Insulin-like Growth Factors (15 papers), Cancer, Hypoxia, and Metabolism (15 papers) and Salmonella and Campylobacter epidemiology (7 papers). Pedro J. Beltran collaborates with scholars based in United States, Australia and United Kingdom. Pedro J. Beltran's co-authors include R K Selander, N. H. Smith, Robert Radinsky, Elaina Cajulis, Frank J. Calzone, Kathleen E. Ferris, Brian Belmontes, James M. Musser, Gordon Moody and Alejandro Cravioto and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Nature Communications.

In The Last Decade

Pedro J. Beltran

52 papers receiving 2.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Pedro J. Beltran United States	25	953	630	488	386	369	52	2.2k
Dan D. Levy United States	24	1.6k 1.7×	141 0.2×	548 1.1×	110 0.3×	63 0.2×	41	2.6k
Carl G. Hellerqvist United States	22	705 0.7×	107 0.2×	84 0.2×	94 0.2×	123 0.3×	54	1.4k
Juan F. Linares United States	23	2.1k 2.2×	60 0.1×	395 0.8×	223 0.6×	179 0.5×	30	3.3k
Mathilde Bonnet France	26	1.2k 1.3×	162 0.3×	738 1.5×	33 0.1×	135 0.4×	64	2.3k
Christina E. DeStefano Shields United States	13	1.9k 2.0×	178 0.3×	752 1.5×	48 0.1×	58 0.2×	15	2.5k
Francesco M. Mancuso Spain	19	789 0.8×	59 0.1×	142 0.3×	488 1.3×	56 0.2×	42	1.6k
Julien Vignard France	22	1.4k 1.4×	131 0.2×	317 0.6×	101 0.3×	96 0.3×	40	1.9k
Shuichi Kusano Japan	26	1.1k 1.2×	72 0.1×	502 1.0×	211 0.5×	73 0.2×	78	2.1k
Thécla Lesuffleur France	28	1.3k 1.3×	216 0.3×	543 1.1×	18 0.0×	108 0.3×	43	2.4k
Jeyanthy Eswaran United Kingdom	27	1.5k 1.6×	53 0.1×	509 1.0×	126 0.3×	261 0.7×	41	2.4k

Countries citing papers authored by Pedro J. Beltran

Since Specialization

Citations

This map shows the geographic impact of Pedro J. Beltran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Pedro J. Beltran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Pedro J. Beltran more than expected).

Fields of papers citing papers by Pedro J. Beltran

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Pedro J. Beltran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Pedro J. Beltran. The network helps show where Pedro J. Beltran may publish in the future.

Co-authorship network of co-authors of Pedro J. Beltran

This figure shows the co-authorship network connecting the top 25 collaborators of Pedro J. Beltran. A scholar is included among the top collaborators of Pedro J. Beltran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Pedro J. Beltran. Pedro J. Beltran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Sharma, Alok K., Jun Pei, Yue Yang, et al.. (2024). Revealing the mechanism of action of a first-in-class covalent inhibitor of KRASG12C (ON) and other functional properties of oncogenic KRAS by 31P NMR. Journal of Biological Chemistry. 300(2). 105650–105650. 11 indexed citations

Tsuruda, Pamela R., Agnieszka Dejda, Sonali Dasgupta, et al.. (2021). UBX1325, a small molecule inhibitor of Bcl-xL, attenuates vascular dysfunction in two animal models of retinopathy. Investigative Ophthalmology & Visual Science. 62(8). 1163–1163. 5 indexed citations

Stice, James P., Yuting Sun, Nancy E. Kohl, et al.. (2021). Abstract P207: BBP-398, a potent, small molecule inhibitor of SHP2, enhances the response of established NSCLC xenografts to KRASG12C and mutEGFR inhibitors. Molecular Cancer Therapeutics. 20(12_Supplement). P207–P207. 8 indexed citations

Mao, Kai, et al.. (2021). Modulation of Glucose Production by Central Insulin Requires IGF-1 Receptors in AgRP Neurons. Diabetes. 70(10). 2237–2249. 14 indexed citations

Lago, M. T. V. T., R. Morganti, R. Schulz, et al.. (2018). IAU volume 14 issue A30 Cover and Front matter. Proceedings of the International Astronomical Union. 14(A30). f1–f23. 1 indexed citations

Mao, Kai, Tahmineh Tabrizian, Fangxia Guan, et al.. (2018). Late-life targeting of the IGF-1 receptor improves healthspan and lifespan in female mice. Nature Communications. 9(1). 2394–2394. 119 indexed citations

Moesta, Achim K., Keegan S. Cooke, Julia Piasecki, et al.. (2017). Local Delivery of OncoVEXmGM-CSF Generates Systemic Antitumor Immune Responses Enhanced by Cytotoxic T-Lymphocyte–Associated Protein Blockade. Clinical Cancer Research. 23(20). 6190–6202. 81 indexed citations

Beltran, Pedro J., Frank J. Calzone, Petia Mitchell, et al.. (2014). Ganitumab (AMG 479) Inhibits IGF-II–Dependent Ovarian Cancer Growth and Potentiates Platinum-Based Chemotherapy. Clinical Cancer Research. 20(11). 2947–2958. 41 indexed citations

Fahrenholtz, Cale D., Pedro J. Beltran, & Kerry L. Burnstein. (2013). Targeting IGF-IR with Ganitumab Inhibits Tumorigenesis and Increases Durability of Response to Androgen-Deprivation Therapy in VCaP Prostate Cancer Xenografts. Molecular Cancer Therapeutics. 12(4). 394–404. 27 indexed citations

10.

Calzone, Frank J., Elaina Cajulis, Petia Mitchell, et al.. (2013). Epitope-Specific Mechanisms of IGF1R Inhibition by Ganitumab. PLoS ONE. 8(2). e55135–e55135. 28 indexed citations

11.

Carnahan, Josette, Pedro J. Beltran, Carol Babij, et al.. (2010). Selective and Potent Raf Inhibitors Paradoxically Stimulate Normal Cell Proliferation and Tumor Growth. Molecular Cancer Therapeutics. 9(8). 2399–2410. 58 indexed citations

12.

Beltran, Pedro J., Petia Mitchell, Elaina Cajulis, et al.. (2009). AMG 479, a fully human anti–insulin-like growth factor receptor type I monoclonal antibody, inhibits the growth and survival of pancreatic carcinoma cells. Molecular Cancer Therapeutics. 8(5). 1095–1105. 113 indexed citations

13.

Beltran, Pedro J., Patricia L. Mitchell, Gordon Moody, et al.. (2008). Effect of AMG 479 on anti-tumor effects of gemcitabine and erlotinib against pancreatic carcinoma xenograft models. Journal of Clinical Oncology. 26(15_suppl). 4617–4617. 197 indexed citations

14.

Beltran, Pedro J., Petia Mitchell, David Hwang, et al.. (2007). Inhibition of endocrine IGF-1 signaling in normal murine tissues and human tumor xenografts with AMG 479, a fully human anti IGF-1R monoclonal antibody. Molecular Cancer Therapeutics. 6. 4 indexed citations

15.

Moody, Gordon, Petia Mitchell, Elaina Cajulis, et al.. (2007). AMG 479, a fully human anti IGF-1 receptor monoclonal antibody, is efficacious against Ewing’s sarcoma and osteosarcoma xenografts. Molecular Cancer Therapeutics. 6. 6 indexed citations

16.

Bergman, Philip J., et al.. (1997). Potent induction of human colon cancer cell uptake of chemotherapeutic drugs by N-myristoylated protein kinase C-α (PKC-α) pseudosubstrate peptides through a P-glycoprotein-independent mechanism. Investigational New Drugs. 15(4). 311–318. 10 indexed citations

17.

Gutman, Mordechai, et al.. (1995). Treatment of nude mice with 4-amidinoindan-1-one2???-amidinohydrazone, a new S-adenosylmethionine decarboxylase inhibitor, delays growth and inhibits metastasis of human melanoma cells. Melanoma Research. 5(3). 147–154. 12 indexed citations

18.

Smith, N. H., Pedro J. Beltran, & R K Selander. (1990). Recombination of Salmonella phase 1 flagellin genes generates new serovars. Journal of Bacteriology. 172(5). 2209–2216. 86 indexed citations

19.

Selander, R K, Pedro J. Beltran, N. H. Smith, et al.. (1990). Genetic population structure, clonal phylogeny, and pathogenicity of Salmonella paratyphi B. Infection and Immunity. 58(6). 1891–1901. 54 indexed citations

20.

Beltran, Pedro J., James M. Musser, Reiner Helmuth, et al.. (1988). Toward a population genetic analysis of Salmonella: genetic diversity and relationships among strains of serotypes S. choleraesuis, S. derby, S. dublin, S. enteritidis, S. heidelberg, S. infantis, S. newport, and S. typhimurium.. Proceedings of the National Academy of Sciences. 85(20). 7753–7757. 171 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact